Researchers are exploring a promising new method to tackle glioblastoma, a particularly deadly brain cancer. The research, which remains years from patient application, involves an experimental therapy leveraging a perceived vulnerability in the disease. The findings, published in Nature, propose a novel approach to fighting this cancer.

Glioblastoma is notorious for its lethality. Most patients survive only 12 to 18 months post-diagnosis. Only about 5% exceed a five-year survival rate. Researchers believe traditional views of glioblastoma as a standalone mass of cancer cells may impede treatment progress. The tumor appears supported by a network of surrounding cells that facilitate its growth and resilience.

Solid tumors like glioblastoma are not just a mass of cancerous cells; they are an ecosystem of cancerous and non-cancerous cells that grow and support each other, said Shan Grewal, a PhD candidate and co-lead author of the study.

Grewal explained that focusing solely on cancer cells might ignore critical biological processes vital to the cancer’s persistence. The research found that therapies should target the tumor-immune ecosystem rather than the cancer cells alone.

The team’s strategy centered on a protein called GPNMB, identified in glioblastoma cells and macrophages, which are immune cells linked to the tumor. This discovery led to developing a CAR-T cell therapy targeting GPNMB, potentially attacking the cancer on multiple fronts.

We identified GPNMB as a protein found on both glioblastoma cells and tumour-supporting macrophages, Grewal stated. This allowed us to use a CAR-T cell strategy that can attack glioblastoma on two fronts at once.

The preclinical tests showed the therapy could eliminate detectable tumors and result in long-term disease-free survival in glioblastoma models, including those derived from human patients.

Insights from the study have shifted focus from targeting cancer cells alone to disrupting the supportive environment around them. Senior author Sheila Singh emphasized viewing glioblastoma as a tumor-immune ecosystem, stating, Our approach attacks both the tumor and the environment that allows it to thrive.

While immunotherapy has shown success in treating some blood cancers, achieving similar results for glioblastoma has been challenging. The tumor’s ability to create a suppressive environment is a significant barrier.

Despite encouraging results, the therapy is not yet ready for clinical trials. Researchers must determine patient selection criteria, optimal delivery methods, and satisfy safety and regulatory requirements. Grewal highlighted these findings as an early-stage development, emphasizing that patients and families should see them as a hopeful step rather than an available treatment.

Grewal concluded, Glioblastoma remains one of the most devastating cancers, and patients deserve new options.